bizhub
Việt Nam remains prime destination for Malaysian investors: MBCV
1.
 |
| Based in Cần Thơ Province since 1974, DHG is one of the leading drug makers in Việt Nam. — Photo tapchiyduoc.com |
Viet Nam News
HÀ NỘI — Hậu Giang Pharmaceutical Joint Stock Company (DHG), Việt Nam’s largest publicly traded drug manufacturer, is planning a cash dividend payout of 35 per cent for 2016.
This figure is 5 per cent higher than originally planned.
It is one of the firm’s contents to be proposed at the annual shareholder meeting to be held on April 18.
As per the proposal, DHG’s net revenue target for 2017 is nearly VNĐ4.37 trillion (US$192 million), up 15.5 per cent against 2016, while its pre-tax profit target is VNĐ800 billion, 5 per cent higher year-on-year.
The company also plans to issue bonus shares to raise capital from owners’ equity at a ratio of 2:1.
Currently, Japanese drug manufacturer Taisho Pharmaceutical Company Limited is DHG’s largest foreign shareholder, with a 24.5 per cent stake.
DHG intends to follow in the steps of Domesco (DMC) and make more room for foreign investors. Domesco is the only firm in the pharmaceutical industry to have raised the ownership of foreign investors up to 100 per cent, which made its share prices double last year.
Based in Cần Thơ Province since 1974, DHG is one of the leading drug manufacturers in the country. Its share price has risen by 30 per cent since the beginning of 2017. — VNS
.jpg)
